CN101084934A - 灵芝孢子油液体胶囊及制备方法 - Google Patents
灵芝孢子油液体胶囊及制备方法 Download PDFInfo
- Publication number
- CN101084934A CN101084934A CN 200710028762 CN200710028762A CN101084934A CN 101084934 A CN101084934 A CN 101084934A CN 200710028762 CN200710028762 CN 200710028762 CN 200710028762 A CN200710028762 A CN 200710028762A CN 101084934 A CN101084934 A CN 101084934A
- Authority
- CN
- China
- Prior art keywords
- spore oil
- ganoderma spore
- capsule
- liquid capsule
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 61
- 239000007788 liquid Substances 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 241000222336 Ganoderma Species 0.000 claims abstract description 48
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 13
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 11
- 238000011049 filling Methods 0.000 claims abstract description 9
- 238000003860 storage Methods 0.000 claims abstract description 8
- 239000007902 hard capsule Substances 0.000 claims abstract description 6
- 239000003921 oil Substances 0.000 claims description 61
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 235000006708 antioxidants Nutrition 0.000 claims description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 229930003427 Vitamin E Natural products 0.000 claims description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 8
- 235000019165 vitamin E Nutrition 0.000 claims description 8
- 229940046009 vitamin E Drugs 0.000 claims description 8
- 239000011709 vitamin E Substances 0.000 claims description 8
- 238000011068 loading method Methods 0.000 claims description 7
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 6
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 6
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims description 6
- 229940030275 epigallocatechin gallate Drugs 0.000 claims description 6
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 6
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 3
- XUSYGBPHQBWGAD-PJSUUKDQSA-N Carnosol Chemical compound CC([C@@H]1C2)(C)CCC[C@@]11C(=O)O[C@@H]2C2=C1C(O)=C(O)C(C(C)C)=C2 XUSYGBPHQBWGAD-PJSUUKDQSA-N 0.000 claims description 3
- MMFRMKXYTWBMOM-UHFFFAOYSA-N Carnosol Natural products CCc1cc2C3CC4C(C)(C)CCCC4(C(=O)O3)c2c(O)c1O MMFRMKXYTWBMOM-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 claims description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 3
- 239000011648 beta-carotene Substances 0.000 claims description 3
- 235000013734 beta-carotene Nutrition 0.000 claims description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 3
- 229960002747 betacarotene Drugs 0.000 claims description 3
- 235000004654 carnosol Nutrition 0.000 claims description 3
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 3
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 claims description 3
- 235000004515 gallic acid Nutrition 0.000 claims description 3
- 229940074391 gallic acid Drugs 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 3
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 2
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims description 2
- 229960002449 glycine Drugs 0.000 claims description 2
- 229960003742 phenol Drugs 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 6
- 238000002156 mixing Methods 0.000 abstract description 6
- 238000007789 sealing Methods 0.000 abstract description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 238000003908 quality control method Methods 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 210000004215 spore Anatomy 0.000 description 65
- 238000012360 testing method Methods 0.000 description 22
- 230000000694 effects Effects 0.000 description 19
- 239000000243 solution Substances 0.000 description 16
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 11
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 11
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 11
- 229940117972 triolein Drugs 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 229940093915 gynecological organic acid Drugs 0.000 description 9
- 150000007524 organic acids Chemical class 0.000 description 9
- 235000005985 organic acids Nutrition 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 238000005303 weighing Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 5
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 5
- 239000005642 Oleic acid Substances 0.000 description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 5
- 238000000227 grinding Methods 0.000 description 5
- 238000009413 insulation Methods 0.000 description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 5
- 239000013558 reference substance Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 240000008397 Ganoderma lucidum Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003228 hemolysin Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 3
- 108010006464 Hemolysin Proteins Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000011344 liquid material Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000012056 semi-solid material Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229960001866 silicon dioxide Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical class NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- KGRVJHAUYBGFFP-UHFFFAOYSA-N 2,2'-Methylenebis(4-methyl-6-tert-butylphenol) Chemical group CC(C)(C)C1=CC(C)=CC(CC=2C(=C(C=C(C)C=2)C(C)(C)C)O)=C1O KGRVJHAUYBGFFP-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 238000001162 G-test Methods 0.000 description 1
- 241001489090 Ganoderma japonicum Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Chemical class CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- FPWNQPQTICPCOM-UHFFFAOYSA-N acetonitrile;propan-2-ol Chemical compound CC#N.CC(C)O FPWNQPQTICPCOM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229930013930 alkaloid Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Chemical class 0.000 description 1
- 239000000194 fatty acid Chemical class 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910001410 inorganic ion Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 1
- 229940043349 potassium metabisulfite Drugs 0.000 description 1
- 235000010263 potassium metabisulphite Nutrition 0.000 description 1
- YLLIGHVCTUPGEH-UHFFFAOYSA-M potassium;ethanol;hydroxide Chemical compound [OH-].[K+].CCO YLLIGHVCTUPGEH-UHFFFAOYSA-M 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 210000003046 sporozoite Anatomy 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000011003 system suitability test Methods 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Chemical class O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
灵芝孢子油液体胶囊及制备方法,涉及一种中药制剂。它是由硬胶囊外壳和内容物组成的液体胶囊剂,内容物是由灵芝孢子油190~200份和抗氧化剂1~10份(重量份)组成。按比例将灵芝孢子油和抗氧化剂混合均匀,加入液体胶囊机的储料罐内,保温于50~70℃,调整装量,定量灌装于胶囊壳中,封口,即得液体胶囊。本品在体内迅速起效,能有效发挥疗效;制备工艺简单,操作方便,产品质量控制方便是适合于工业生产的安全可靠的制备方法;产品外形美观、透明度高,密封性好,减低了装量差异,含量准确;本品稳定性好。
Description
技术领域
本发明涉及一种中药制剂,具体是涉及一种含有灵芝孢子油为活性成份的灵芝孢子油液体胶囊剂。
背景技术
灵芝是担子菌纲多孔菌科(Polyproraceae)灵芝属(Ganoderma)真菌赤芝[Ganoderma lucidium(Leyss.ex Fr.)Karst.]和紫芝[Ganodermajaponicum(Fr.)Lloyd.]的总称,具有扶正固本等功效,被《本经》称为上品。灵芝孢子(Ganoderma lucidiumspore)是赤芝生长成熟期从菌盖弹射出来极其细小的孢子,为灵芝的生殖细胞,具有灵芝的全部遗传活性物质。灵芝孢子的化学成分复杂,文献报道有以下几类:甾醇类、三萜类、生物碱类、脂肪酸类、内酯、蛋白质和氨基酸类、糖肽类、维生素类、胡萝卜素、和无机离子类等。灵芝孢子油是从灵芝孢子中提取出来的一种疏水性油类物质。据文献[江苏药学与临床研究,2001,9(2):55]报导,我国科学家研究发现脂质是灵芝孢子的抗病“主力”。灵芝孢子提取的脂质活性物质为灵芝孢子油。
灵芝孢子的药理作用主要有抗肿瘤、免疫调节、调节血脂以及对神经、心血管和呼吸系统有调节改善作用。关于灵芝孢子的产品也越来越多,如灵芝孢子油、灵芝孢子粉及其它们的制剂有灵芝孢子油软胶囊、灵芝孢子油脂肪乳注射剂、灵芝孢子油脂肪乳口服剂、灵芝孢子胶囊、灵芝孢子片、灵芝孢子散剂等。但灵芝孢子油液体胶囊还未见报导。
发明内容
本发明的目的是提供一种配方简单、合理,服用安全,稳定性好,生物利用度高的的灵芝孢子油新剂型及其制备方法。
本发明的技术方案:灵芝孢子油的新剂型,是由硬胶囊外壳和内容物组成的液体胶囊剂,所述的内容物由下述重量份的原料组成:灵芝孢子油190~200份和抗氧化剂1~10份。
由于灵芝孢子油含有三萜酸、麦角甾醇、不饱和脂肪酸,易氧化变质,为了解决抗氧化问题,所以有必要添加一定量的抗氧化剂。常规的抗氧化剂有焦亚硫酸钠、焦亚硫酸钾等无机化学品,及有机的抗氧剂:维生素E、抗坏血酸、β-胡萝卜素、表没食子儿茶素、表没食子儿茶素没食子酸酯、表儿茶素没食子酸酯、儿茶素、鼠尾草酚、迷迭香酚、山梨糖醇、麦芽糖醇、木糖醇、蛋氨酸、色氨酸、苯丙氨酸、脯氨酸、α-醋酸生育酚、抗坏血酸、甘氨酸、乙二胺四乙酸、二丁基羟基甲苯等。无机化学品容易产生副作用,影响药物的安全性。本发明优选了有机的抗氧化剂如维生素E、抗坏血酸、没食子酸、表没食子儿茶素、表没食子儿茶素没食子酸酯、鼠尾草酚、迷迭香酚、山梨糖醇、甘氨酸、β-胡萝卜素、丁基羟基茴香醚、α-醋酸生育酚中的一种或二种以上。以采用维生素E最佳,维生素E等本身是一种营养物质,食用安全没有副作用,与药品配伍也没有其他不良影响,不影响药物的正常崩解,与胶囊壳体、密封材料也不会发生反应。
关于抗氧化剂的用量,通过综合考虑生产成本、抗氧化效果等指标确定其最佳的用量,即可以保证抗氧化效果又能使液体胶囊内容物又有良好的沉降比和药物分散性。
本发明内容物优选由下述重量份的原料组成:灵芝孢子油199份,维生素E 1份。
所述的灵芝孢子油液体胶囊的制备方法,是按上述药物内容物的比例将灵芝孢子油190~200份和抗氧化剂1~10份(重量份)搅拌混合均匀,然后加入液体胶囊机的储料罐内,保温于50~70℃,调整装量,定量灌装于硬胶囊壳中,封口,即得。
同时本发明更强调了药物的安全性和成本,所以在保证药物的功效、稳定的同时尽可能少使用辅料,减少辅料带来的副作用和不良影响,所以本发明配方简单,成本相对较低,且制剂过程有利于劳动保护和防止交叉污染。
液体胶囊是一种新型剂型,由液体或半固体状物质灌装入硬胶囊中,采用先进技术进行胶囊密封制得,与其他剂型相比,因其内含物为液体或半固体物质,因而具有容易吸收,起效迅速,生物利用度高等特点,同时,液体胶囊无臭无味,容易吞服,不粘结,不渗漏,携带方便,服用依从性好。
下面通过试验说明本发明的有益效果
一、药效试验证明灵芝孢子油液体胶囊的增强免疫作用。
试验条件:
样品:以超临界CO2提取工艺获得的灵芝孢子油,以本发明的技术制备灵芝孢子油液体胶囊,规格400mg/粒。为了更好地检测孢子油的功效,按60公斤成人为0.04g/kg b.w,设计低、中、高剂量组。各实验剂量组所需浓度均用玉米油稀释样品配成。
组别与剂量:设玉米油对照组和低、中、高三个剂量组,剂量如下:
(1)低剂量组0.02g/kg b.w,相当于推荐日服用量5倍。
(2)中剂量组0.40g/kg b.w,相当于推荐日服用量10倍。
(3)中剂量组1.20g/kg b.w,相当于推荐日服用量30倍
动物:SPF级昆明种雌性小白鼠,6~8周龄(体重:18~22g)
给药途径:每天按10ml/kg b.w量灌胃动物给予受试动物。
实验条件:实验温度23℃~24℃,湿度58%~60%。
实验数据统计所得数据采用SAS软件进行分析。
1、灵芝孢子油液体胶囊对小鼠的迟发型变态反应的影响见下表
灵芝孢子油液体胶囊对小鼠迟发型变态反应的影响
组别 | 剂量(g/kg b.w) | 动物数(只) | 足跖增厚(mm) | P值(与对照组比) |
对照组低剂量中剂量高剂量F值 | 0.00.20.41.2 | 12121212 | 0.38±0.270.59±0.290.50±0.280.74±0.313.249 | >0.05>0.05<0.01 |
试验结果:高剂量组足跖增厚值与对照组比较,差异有统计学意义,表明该试验结果为阳性。
2、灵芝孢子油液体胶囊对ConA诱导的小鼠脾淋巴细胞转化反应见表
灵芝孢子油液体胶囊对小鼠淋巴细胞转化反应的影响
组别 | 剂量(g/kg b.w) | 动物数(只) | 光密度差值 | P值(与对照组比) |
对照组低剂量中剂量高剂量F值 | 0.00.20.41.2 | 12121212 | 0.118±0.540.164±0.580.187±0.590.179±0.433.692 | <0.05<0.01<0.05 |
试验结果:各剂量组光密度值与对照组比较,差异均有统计学意义,表明灵芝孢子油液体胶囊对脾淋巴细胞转化反为阳性结果。
3、灵芝孢子油液体胶囊对受试动物血清溶血素抗体滴度反应见表
灵芝孢子油液体胶囊对小鼠血清溶血素抗体滴度反应的影响
组别 | 剂量(g/kg b.w) | 动物数(只) | 抗体体积(mm) | P值(与对照组比) |
对照组低剂量中剂量高剂量F值 | 0.00.20.41.2 | 12121212 | 48.16±4.8261.21±1.3485.49±0.7882.74±8.239.726 | >0.05<0.01<0.01 |
试验结果:由表可见,中、高剂量组的抗体体积数均高于对照组,差异比较有统计学意义,表明灵芝孢子油液体胶囊对受试动物血清溶血素抗体滴度反应为阳性。
4、灵芝孢子油液体胶囊对小鼠碳廓清吞噬功能的影响见表。
灵芝孢子油液体胶囊对小鼠碳廓清吞噬功能的影响
组别 | 剂量(g/kg b.w) | 动物数(只) | 抗体体积(mm) | P值(与对照组比) |
对照组低剂量中剂量高剂量F值 | 0.00.20.41.2 | 10101010 | 3.57±0.714.92±1.245.15±1.145.63±1.395.857 | <0.05<0.01<0.01 |
试验结果:各剂量组吞噬指数与对照组比较,差异均有统计学意义。表明灵芝孢子油液体胶囊对小鼠碳廓清吞噬作用为阳性结果。
5、结论
小鼠经口每日分别给予灵芝孢子油液体胶囊0.20、0.40、1.20g/kg b.w,相当于推荐日服用量5、10、30倍,试验时间共30天。结果显示:
(1)绵羊红细胞诱导的小鼠迟发型变态反应试验(足跖增厚法)结果阳性;
(2)小鼠脾淋巴细胞转化实验阳性,样品具有增强免疫功能作用;
(3)绵羊红细胞免疫小鼠血清溶血素试验(血凝法)结果阳性,样品具有增强体液免疫功能作用;
(4)小鼠碳廓清试验结果阳性,样品具有增强单核.巨噬细胞功能作用。
二、稳定性试验
1、光照效果试验
取实施例1中制备的灵芝孢子油液体胶囊装入透明密封容器中,于光照强度4500Lx下放置5,10天后取样检查。结果见表1。
表1样品光照试验(4500Lx)结果
注:“000”为“甘油三油酸酯”的简称(以下同)
结论:按照本发明提供的技术方案制备的灵芝胞子油液体胶囊在光照(4500Lx)条件下,性状、鉴别、崩解时限、总有机酸量及甘油三油酸酯量均无明显变化。
2、低温效果实验
取实施例1中制备的灵芝孢子油液体胶囊置于8℃的冰箱中,放置5、10天后取样进行检查,结果见表2。
表2样品低温试验(8℃)结果
结论:按照本发明提供的技术方案制备的灵芝孢子油液体胶囊在低温(8℃)条件下,性状、鉴别、崩解时限、总有机酸量及甘油三油酸酯量均无明显变化。
3、高温效果实验
取实施例5中制备的灵芝孢子油液体胶囊置于60℃的恒温箱中,放置5、10天后取样进行检查,结果见表3。
表3样品高温试验(60℃)结果
结论:按照本发明提供的技术方案制备的灵芝孢子油液体胶囊在高温(60℃)条件下,性状、鉴别、崩解时限、总有机酸量及甘油三油酸酯量均无明显变化。
4、高湿效果实验
取实施例1中制备的灵芝孢子油液体胶囊置于相对湿度92.5%条件下,放置5、10天后取样进行检查。结果见表4。
表4样品高湿试验(相对湿度92.5%)结果
结论:在高湿(RH=92.5%)条件下,本品吸湿,性状发生改变,胶囊壳彭胀变软,提示按照本发明提供的技术方案制备的灵芝孢子油液体胶囊应密封保存。
5、加速稳定性效果试验:
取实施例1中制备的灵芝孢子油液体胶囊铝塑泡着包装,置于40℃,RH75%条件下贮存,分别于0、1、2、3、6个月取样,按考察项目检查,结果见表5。 表5加速稳定性效果试验结果
实验结果表明,按照本发明提供的技术方案制备的灵芝孢子油液体胶囊质量稳定性好。
含量测定方法:
1.总有机酸量测定取本品5粒,剪开,倾出内容物,精密称取0.8g,加中性乙醇(对酚酞指示液显中性)10ml,精密加入氢氧化钾乙醇溶液(0.5mol/L)25ml,置水浴中加热回流1.5小时,放冷,用中性乙醇10ml冲洗冷凝器,合并溶液,加酚酞指示液3滴,用盐酸液(0.5mol/L)滴定至粉红色消失,并将滴定的结果用空白试验校正。每1ml的盐酸液(0.5mol/L)相当于282.47mg的C18H34O2。
式中A-供试品消耗盐酸液(0.5mol/L)的毫升数
B-空白试验消耗盐酸液(0.5mol/L)的毫升数
C-盐酸液的摩尔浓度(0.5mol/L)
G-供试品的重量(g)
2.甘油三油酸酯含量测定照高效液相色谱法(《中国药典》2005年版一部附录VI D)测定:
色谱条件与系统适用性试验以十八烷基硅烷键合硅胶为填充剂;以乙腈--异丙醇(53∶47)为流动相;蒸发光散射检测器检测。理论板数按OOP计不得少于3000。
对照品溶液的制备精密称取甘油三油酸酯对照品适量,加流动相溶解,并制成每1ml含0.15mg的溶液,摇匀,即得。
供试品溶液的制备取本品5粒,剪开,倾出内容物,精密称定0.1g,置100ml量瓶中,精密加入流动相溶解并稀释至刻度,摇匀,过滤,取续滤液即得。
测定法分别精密吸取对照品溶液5μl、10μl,供试品溶液各5~10μl,注入液相色谱仪,测定,用外标二点法对数方程计算,即得。
3.灵芝酸E的TLC鉴别:
取本品15粒,剪开,倾出内容物,加石油醚50ml溶解,加入已处理好的硅胶柱(10g,18mm×400mm)上,加入150ml乙酸乙酯∶石油醚(60~90℃)=75∶25的混合溶液洗脱,弃去洗脱液,硅胶柱继续加入150ml乙酸乙酯∶甲醇=90∶10的混合溶液洗脱,收集洗脱液,回收溶剂至干,残渣加甲醇2ml溶解,作为供试品溶液。另取灵芝酸E对照品1mg,加甲醇2ml溶解,作为对照品溶液。照薄层色谱法(中国药典2005年版一部附录VIB)试验,吸取上述二种溶液各10μl,分别点于同一硅胶GF254薄层板上,以环己烷-乙酸乙酯-冰乙酸(4.3∶5.5∶0.2)为展开剂,展开,取出,晾干,置紫外光灯(254nm)下检识。供试品色谱中,在与灵芝酸E对照品色谱相应的位置上显相同颜色的暗色斑点。
本发明的有益效果:
1、本发明将灵芝孢子油制成液体胶囊,由于其内容物为液体,所以在体内迅速起效,能有效发挥疗效,生物利用度高等特点。
2、采用本发明所提供的方法,工艺流程简单,操作方便,产品质量控制方便有可操作性,是适合于工业生产的安全可靠的制备方法。
3、产品外形美观、透明度高,密封性好,减低了装量差异,含量准确。
4、由于减低了外壳的氧通透性和物质迁移,而且外壳的溶解速度变化小;因此制剂的稳定性得以提高,其崩解速度、有效成分含量均比较稳定,具有良好的耐热、耐湿性以及坚韧度。
5、省去了生产软胶囊时所必须的化胶、压制、干燥等设备和工艺,大幅降低生产成本,既适合于工业生产也适用于小批量生产。
6、产品具有良好的提高具体免疫功能的作用;具有良好的经济效益和社会效益及应用前景。
下面结合实施例阐述本发明的技术方案
具体实施方式
实施例1
称取灵芝孢子油398g、维生素E 2g,混合、搅拌、研磨均匀得到混合液;将得到的混合液加入液体胶囊机的储料罐内,50~70℃保温,调整装量,定量灌装于胶囊壳中,封口,即得,得灵芝孢子油液体胶囊1000粒,每粒含总有机酸量以油酸(C18H34O2)计算为0.382g,含000(甘油三油酸酯)61.1mg。
实施例2
称取灵芝孢子油395g、维生素E 5g,混合、搅拌、研磨均匀得到混合液;将得到的混合液加入液体胶囊机的储料罐内,50~70℃保温,调整装量,定量灌装于胶囊壳中,封口,即得,得灵芝孢子油液体胶囊1000粒,每粒含总有机酸量以油酸(C18H34O2)计算为0.378g,含000(甘油三油酸酯)59.2mg。
实施例3
称取灵芝孢子油380g、抗坏血酸20g,混合、搅拌、研磨均匀得到混合液;将得到的混合液加入液体胶囊机的储料罐内,50~70℃保温,调整装量,定量灌装于胶囊壳中,封口,即得,得灵芝孢子油液体胶囊1000粒,每粒含总有机酸量以油酸(C18H34O2)计算为0.363g,含000(甘油三油酸酯)57.2mg。
实施例4
称取灵芝孢子油398g、没食子酸2g,混合、搅拌、研磨均匀得到混合液;将得到的混合液加入液体胶囊机的储料罐内,50~70℃保温,调整装量,定量灌装于胶囊壳中,封口,即得,得灵芝孢子油液体胶囊1000粒,每粒含总有机酸量以油酸(C18H34O2)计算为0.379g,含000(甘油三油酸酯)59.7mg。
实施例5
称取灵芝孢子油390g、甘氨酸10g,混合、搅拌、研磨均匀得到混合液;将得到的混合液加入液体胶囊机的储料罐内,50~70℃保温,调整装量,定量灌装于胶囊壳中,封口,即得,得灵芝孢子油液体胶囊1000粒,每粒含总有机酸量以油酸(C18H34O2)计算为0.372g,含000(甘油三油酸酯)58.5mg。
Claims (4)
1、一种灵芝孢子油的新剂型,其特征在于:由内容物和硬胶囊外壳组成的液体胶囊剂,所述的内容物由下述重量份的原料组成:灵芝孢子油190~200份和抗氧化剂1~10份。
2、根据权利要求1所述的灵芝孢子油的新剂型,其特征在于:所述的抗氧化剂是维生素E、抗坏血酸、没食子酸、表没食子儿茶素、表没食子儿茶素没食子酸酯、鼠尾草酚、迷迭香酚、山梨糖醇、甘氨酸、β-胡萝卜素、丁基羟基茴香醚、α-醋酸生育酚中的一种或二种。
3、根据权利要求1所述的灵芝孢子油新剂型,其特征在于:所述的内容物由下述重量份的原料组成:灵芝孢子油199份和维生素E1份。
4、一种如权利要求1所述的灵芝孢子油新剂型的制备方法,其特征在于:按比例将灵芝孢子油和抗氧化剂混合均匀,加入液体胶囊机的储料罐内,保温于50~70℃,调整装量,定量灌装于硬胶囊壳中,封口,即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200710028762 CN101084934A (zh) | 2007-06-22 | 2007-06-22 | 灵芝孢子油液体胶囊及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200710028762 CN101084934A (zh) | 2007-06-22 | 2007-06-22 | 灵芝孢子油液体胶囊及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101084934A true CN101084934A (zh) | 2007-12-12 |
Family
ID=38936217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200710028762 Pending CN101084934A (zh) | 2007-06-22 | 2007-06-22 | 灵芝孢子油液体胶囊及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101084934A (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010133009A1 (zh) * | 2009-05-18 | 2010-11-25 | 南京中科集团股份有限公司 | 一种含灵芝孢子油的抗肿瘤中药制剂及其制备方法 |
CN103627522A (zh) * | 2013-11-14 | 2014-03-12 | 浙江大学城市学院 | 灵芝孢子油纯天然复合抗氧化剂及提高其稳定性的方法 |
CN103622015A (zh) * | 2013-11-28 | 2014-03-12 | 江西仙客来生物科技有限公司 | 灵芝孢子油ve软胶囊 |
CN107156332A (zh) * | 2017-06-22 | 2017-09-15 | 利康行(北京)生物科技有限公司 | 一种增强免疫力的复方保健品 |
CN111304091A (zh) * | 2019-11-28 | 2020-06-19 | 昆明理工大学 | 一种提高灵芝细胞培养中灵芝酸含量的方法 |
CN116036139A (zh) * | 2022-12-15 | 2023-05-02 | 福建三明草本宝藏生物工程有限公司 | 一种具有增强免疫力的混合型孢子油组合物 |
-
2007
- 2007-06-22 CN CN 200710028762 patent/CN101084934A/zh active Pending
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010133009A1 (zh) * | 2009-05-18 | 2010-11-25 | 南京中科集团股份有限公司 | 一种含灵芝孢子油的抗肿瘤中药制剂及其制备方法 |
CN103627522A (zh) * | 2013-11-14 | 2014-03-12 | 浙江大学城市学院 | 灵芝孢子油纯天然复合抗氧化剂及提高其稳定性的方法 |
CN103622015A (zh) * | 2013-11-28 | 2014-03-12 | 江西仙客来生物科技有限公司 | 灵芝孢子油ve软胶囊 |
CN107156332A (zh) * | 2017-06-22 | 2017-09-15 | 利康行(北京)生物科技有限公司 | 一种增强免疫力的复方保健品 |
CN111304091A (zh) * | 2019-11-28 | 2020-06-19 | 昆明理工大学 | 一种提高灵芝细胞培养中灵芝酸含量的方法 |
CN116036139A (zh) * | 2022-12-15 | 2023-05-02 | 福建三明草本宝藏生物工程有限公司 | 一种具有增强免疫力的混合型孢子油组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cheeseman et al. | Biokinetics in humans of RRR-α-tocopherol: the free phenol, acetate ester, and succinate ester forms of vitamin E | |
CN101084934A (zh) | 灵芝孢子油液体胶囊及制备方法 | |
Yuen et al. | Effect of mixed-tocotrienols in hypercholesterolemic subjects | |
Parrish et al. | Determination of vitamin E in foods—a review | |
Gray et al. | Mycotoxins in root extracts of American and Asian ginseng bind estrogen receptors α and β | |
CN101380340B (zh) | 一种破壁灵芝孢子粉抗氧化的生产方法 | |
Jadoon et al. | Spectrophotometric method for the determination of Vitamin A and E using Ferrozine-Fe (II) complex | |
CN117233309A (zh) | 一种多种维生素注射剂杂质的检测方法 | |
CN103512971A (zh) | 一种鸦胆子油口服干乳剂的质量控制方法 | |
CN101961426A (zh) | 普洱茶的提取物及提取方法 | |
CN107362151A (zh) | 一种骨化三醇液体硬胶囊剂及其制备方法、应用 | |
CN105326880A (zh) | 油菜花粉水溶性提取物及其制备方法与应用 | |
CN112022833B (zh) | 一种恩杂鲁胺药物组合物及其制备方法 | |
Zheng et al. | Biosynthesis and pharmacokinetics of Panax notoginseng enteric-coated soft capsules | |
CN100473389C (zh) | 控制灵芝孢子、灵芝孢子油及其制剂质量的方法 | |
US3993756A (en) | Antilipemic agent containing a soybean oil fraction | |
Bardot et al. | Benefits of the ipowder® extraction process applied to Melissa officinalis L.: improvement of antioxidant activity and in vitro gastro-intestinal release profile of rosmarinic acid | |
CN101961423A (zh) | 普洱茶提取物及其制备方法 | |
CN100515434C (zh) | 一种灵芝孢子油、灵芝孢子粉及其制剂的质量控制方法 | |
CN100417378C (zh) | 冬凌草甲素包合物及含有该包合物的药物制剂 | |
CN110057936A (zh) | 一种维生素e的含量测定方法 | |
CN102247413A (zh) | 续断总皂苷及木通皂苷d的降血脂作用 | |
CN101279055A (zh) | 参芪花粉制剂新的治疗用途及质量控制方法 | |
CN100998617B (zh) | 心达康制剂的含量测定方法 | |
CN103675135A (zh) | 一种中药组合物的含量测定方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20071212 |